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The first World Health Organization (WHO) International Standards (ISs) for nucleic acid 17 
amplification techniques (NAT or NAAT) were established two decades ago with the initial 18 
focus on blood screening for three major viral targets - hepatitis C virus, hepatitis B virus and 19 
human immunodeficiency virus type 1. These reference materials have subsequently found 20 
utility in the diagnosis and monitoring of a wide range of infectious diseases in clinical 21 
microbiology laboratories worldwide. WHO collaborating centers develop ISs and coordinate 22 
international studies for their evaluation. The WHO Expert Committee on Biological 23 
Standardization is responsible for the endorsement of new standardization projects as well as 24 
establishment of new and replacement ISs. Potencies of ISs are defined in “international 25 
units” (IU), and the reporting in IU by assays calibrated with an IS (or secondary standards 26 
traceable to the IS) facilitates comparability of results between different assays and 27 
determination of assay parameters such as analytical sensitivities. 28 
 29 
INTRODUCTION 30 
Nucleic acid amplification technology (NAT or NAAT) has become a staple in both the 31 
clinical microbiology laboratory and in blood screening centers for the detection of microbial 32 
pathogens, particularly viruses. This was not the case more than two decades ago with the 33 
transmission of hepatitis B/C viruses (HBV and HCV) and human immunodeficiency virus 34 
type 1 (HIV-1) to recipients of therapeutic plasma derivatives or blood components, when it 35 
was realized that closing the serological window using NAT testing improved blood safety. In 36 
the following years, considerable effort was invested in the implementation of NAT screening 37 
for blood and plasma donors and introducing this technology for diagnostic testing in clinical 38 
microbiology laboratories using both commercial as well as laboratory developed tests 39 
(LDTs). However, assay sensitivities and specificities varied widely between laboratories, 40 
contamination by amplicons was problematic and assays lacked standardization. During this 41 
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time, the World Health Organization (WHO), as the global institution for setting standards for 42 
health systems, was requested to establish internationally accepted reference materials, e.g. 43 
International Standards (ISs), for NAT assays. The ISs are measurement standards with a 44 
defined concentration of a specific analyte that enable the comparison of results between 45 
different assays and different laboratories. These reference materials were initially prepared 46 
from viremic plasma donations (reflecting the type of sample being tested) and subsequently 47 
freeze dried. The complex nature of donor and clinical samples, such as plasma or sera, means 48 
that nucleic acid measurement of a specific pathogen cannot be determined by physico-49 
chemical methods. Before nucleic acid concentrations can be determined, samples must be 50 
extracted and undergo in vitro amplification and detection; therefore results cannot simply be 51 
reported in International System of Units (SI)-related units such as kilograms or moles. For 52 
WHO ISs representing complex biological materials, the WHO took the approach of adopting 53 
the International Unit (IU); the IU has been used to define potencies of all ISs for NAT-based 54 
assays. 55 
In this review, we discuss the steps involved in prioritization and in the preparation and 56 
characterization of WHO ISs, their establishment, replacement and realization of their value 57 
in harmonizing results between different assays and different laboratories. 58 
 59 
SETTING PRIORITIES FOR NAT STANDARDIZATION 60 
An international working group Standardization of Genomic Amplification Techniques 61 
(SoGAT) was established in 1995, on behalf of the WHO, which has since been coordinated 62 
by the National Institute for Biological Standards and Control (NIBSC; United Kingdom). 63 
Initially, the focus was to standardize NAT assays for blood-borne pathogens important in the 64 
field of blood safety; however, standardization was also essential in the diagnosis and 65 
monitoring of infectious diseases in the clinical setting. WHO ISs for pathogens such as HCV, 66 
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HBV and HIV-1 have been widely used in microbiology laboratories as well and new 67 
standards have been prepared for increasing numbers of clinically important pathogens. 68 
The first WHO IS for NAT assays established in 1997 was HCV (1), this was followed by 69 
hepatitis B virus (HBV) and HIV-1 in 1999 (2, 3). Subsequently, ISs have been established 70 
for other blood-borne viruses including parvovirus B19 (B19V), hepatitis A virus (HAV), 71 
HIV-2, hepatitis E virus (HEV) and hepatitis D virus (HDV) (4-8) as well as human 72 
cytomegalovirus (CMV) and Epstein-Barr virus (EBV) (9, 10). Several of these standards, 73 
like those for HCV, HBV and HIV-1, have been essential for introducing regulatory 74 
requirements for testing of blood and plasma donations as well as being used by clinical 75 
microbiology laboratories for determination of viral loads. In the field of transplantation, ISs 76 
have been prepared for CMV, EBV, BK virus (BKV), JC virus (JCV) as well as human 77 
herpesvirus type 6b (HHV6b) (9-13). Other ISs established include ones for the parasites 78 
Plasmodium falciparum and Toxoplasma gondii (14, 15) as well as a standard for 79 
Mycoplasma species (16). More recently, emerging diseases have been addressed with the 80 
establishment of ISs for Zika virus (ZIKV) and chikungunya virus (CHIKV) (17, 18). Slightly 81 
different types of WHO standards, termed reference reagents have been prepared for Ebola 82 
virus (19) and the four different dengue virus serotypes (20). Although initially developed for 83 
vaccine studies, ISs have been prepared for human papillomavirus type 16 and 18 (21), in this 84 
case, based on plasmids representing the viral genomes due to lack of native or cultured 85 
source materials. Current WHO ISs and reference reagents for NAT are shown in Table 1. 86 
The SoGAT group has met at least annually since it was established, collectively identifying 87 
priority pathogens where there is a need for NAT-standardization and coordinating 88 
international studies to develop and evaluate these materials. The need for specific standards 89 
is determined through discussions with the scientific and medical community worldwide 90 
through the SoGAT forum, through WHO programs in disease areas such as malaria and 91 
tuberculosis, with input from manufacturers of in vitro diagnostic devices (IVDs) and by the 92 
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three official WHO collaborating centers in the fields of blood and IVDs: NIBSC, the Paul-93 
Ehrlich-Institut (PEI, Germany) and the U.S. Food and Drug Administration, Center for 94 
Biologics Evaluation and Research (FDA/ CBER, USA).The SoGAT meetings allow for the 95 
discussion of results from international collaborative studies prior to submission and review 96 
by the WHO Expert Committee on Biological Standardization (ECBS). The ECBS plays a 97 
formal role in the establishment of ISs and related reference materials, and committee 98 
members are scientific experts from national control agencies, research institutes, academia, 99 
public health bodies and the pharmaceutical industry. All new proposed international 100 
standardization projects are subject to review by the ECBS before endorsement. 101 
Occasionally, special topics have been discussed at extraordinary SoGAT meetings; examples 102 
include addressing the problems with detection of different genotypes of B19V and how to 103 
improve standardization (22). 104 
 105 
TYPES OF WHO REFERENCE MATERIALS 106 
International Standards (ISs) and their role 107 
ISs are measurement standards and are assigned an internationally agreed unitage in IU (23). 108 
The potencies of ISs are determined by consensus means through international collaborative 109 
studies, using a range of methods typically in routine use by participating laboratories. In the 110 
case of NAT assays, potencies are determined by a combination of end-point dilution analysis 111 
for qualitative assays and, for example, by “copy numbers” or “genome equivalents” for 112 
quantitative assays. Although the IU is arbitrary in theory, in practice, it corresponds to the 113 
mean overall potency (“NAT-detectable units”) reported by participating laboratories. 114 
Adoption of the IU also avoids the issue of copy number, the definition of which is assay-115 
dependent and which also implies, misleadingly, that material is traceable to an SI unit. 116 
Repeatedly, during studies to evaluate new ISs, quantitative reporting of concentrations of 117 
samples in copy numbers typically varies over several orders of magnitude. This demonstrates 118 
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that copy number is not a robust measure that can be compared readily between laboratories; 119 
the use of the IU allows better comparison of results. 120 
WHO ISs are considered as the highest order, international conventional calibrators in 121 
accordance with ISO 17511:2003 (In vitro diagnostic medical devices - Measurement of 122 
quantities in biological samples - Metrological traceability of values assigned to calibrators 123 
and control materials) (24). The principal use of ISs is in the calibration of secondary 124 
standards (Figure 1), traceable in IU and for evaluation of critical assay parameters such as 125 
analytical sensitivities and quantification range, including upper and lower limits of 126 
quantification. The preparation and calibration of secondary standards is described in detail 127 
elsewhere (25). Uncertainty values are not assigned to WHO ISs, since the IU is an arbitrary 128 
unit and variance is associated with that of the vial content. 129 
In Europe, the new Regulation on in vitro diagnostic medical devices (CE-IVDs) stipulates 130 
the design requirements for calibration of assays using “reference materials of a higher 131 
metrological order” (26). Furthermore, the Regulation requires metrological traceability of 132 
values assigned to calibrators and control materials using “reference materials…of higher 133 
order” which should be communicated to the user. In addition, the “Common Technical 134 
Specifications” state that WHO ISs should be included in the performance evaluation and the 135 
reporting of test results in IU for “high risk” IVDs (e.g. for quantitation of HIV-1, HBV, or 136 
HCV) (27). Furthermore, regulatory requirements for testing of biologics may define minimal 137 
sensitivity for suitable assays based on WHO ISs. Examples are national requirements for 138 
blood screening markers (e.g. HIV-1 RNA, HCV RNA in Germany) or European regulation 139 
of plasma derivatives (e.g. HCV RNA in manufacturing plasma pools). 140 
Representatives of the US FDA/CBER participate on a regular basis in the international 141 
standardization efforts undertaken by WHO. In contrast to the EU, there is no legal 142 
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requirement in the US to use WHO ISs for assay calibration; however, panel members used 143 
by FDA/CBER for lot release of NAT tests have been calibrated against WHO ISs (28, 29). 144 
When an IS is established for the first time, it is designated the 1
st
 IS, upon its replacement it 145 
is termed the 2
nd
 IS, the 3
rd
 IS and so on and with each subsequent standard replacing its 146 
predecessor as the highest order reference standard. Replacement of ISs is discussed in more 147 
detail below. 148 
Reference reagents and international reference panels 149 
In addition to WHO ISs, there are other types of standards established by the WHO ECBS, 150 
these include Reference Reagents (RRs) as well as International Reference Panels (IRPs). 151 
Both RRs and IRPs are prepared and evaluated using principles similar to WHO ISs. 152 
The IRPs consist of different genotypes or important strains of pathogens with diverse global 153 
distribution; examples of such panels include HIV, HBV, B19V and HEV (Table 2) (30-35). 154 
The role of IRPs is to help ensure consistent detection of pathogen variants, particularly when 155 
being used for assay validation purposes. They have been important tools for improvement in 156 
assay performance where detection of specific variants has been sub-optimal. Usually, no 157 
unitage is assigned to members of IRPs. However, the data on assay performance are included 158 
in the collaborative study reports published on the WHO website, providing a range of 159 
potencies reported for individual panel members. 160 
In the case of RRs, these are usually interim standards with a unitage defined in units rather 161 
than IU. Upon further characterization, RRs may be established as ISs and the unitage defined 162 
in IU. Examples of RRs include NAT standards for Ebola virus, established in response to the 163 
Ebola crisis in 2014, and based upon recombinant lentivirus vectors to avoid biosafety issues 164 
(19). More recently, four RRs have been established for dengue types 1-4; because of the 165 
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genetic differences between the types it was not possible to select a single strain as an IS, 166 
consequently each type has a separate unitage (20). 167 
 168 
PREPARATION AND ESTABLISHMENT OF WHO REFERENCE MATERIALS 169 
Characterization and preparation of candidate standards 170 
The processes involved from the identification of the scientific need to develop a standard 171 
through establishment and ultimately its replacement are shown in Figure 2. The procedure to 172 
establish WHO standards is extremely rigorous (23) and undertaken by one of the three WHO 173 
Collaborating Centers on behalf of the WHO. 174 
The development of a new standard starts with the identification and preparation of a suitable 175 
stock material which may either be viremic plasma – for example for HCV, HBV and HEV or 176 
parasitemic whole blood (Plasmodium falciparum) (14), or pathogens propagated in culture. 177 
More rarely, animals have been used as alternative starting materials where sources of native 178 
materials are unavailable or not of insufficiently high titer, and example of this is the 179 
propagation of Toxoplasma gondii tachyzoites in mice (15). HPV ISs have been based on the 180 
preparation of plasmid DNAs diluted in human genomic DNA (21). An estimate is made of 181 
the concentration of the stock material and identity testing is performed e.g. by sequence 182 
analysis, and where material has been obtained from blood or plasma, donations are screened 183 
to ensure the absence of other blood-borne pathogens other than the target in question. Strains 184 
are selected to reflect those with widespread distribution and global importance whenever 185 
possible. Occasionally, materials may be inactivated depending on feasibility combined with 186 
biosafety concerns; such procedures should be validated, however, this may not be possible 187 
for some pathogens where suitable cell culture systems are not available. To facilitate 188 
distribution worldwide, WHO standards are usually lyophilized. Therefore, formulation is an 189 
important factor to consider and this is fairly straightforward where viremic plasma is used 190 
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and the standards will be further diluted in this matrix when used in the recipient laboratories. 191 
However, where testing of certain pathogens can be performed on different types of matrices, 192 
e.g. whole blood, urine, cerebrospinal fluid (CSF) as well as plasma, cultured viral and 193 
microbial strains have been formulated in solutions containing excipients (buffers, sugars, 194 
stabilizers etc.) that allow further dilution of the standard into the appropriate type of matrix. 195 
The final formulation should not cause any interference with the NAT assays, e.g. decrease in 196 
extraction efficiency or inhibition of amplification. 197 
When the bulk standard preparation is dispensed into either vials or ampoules, the coefficient 198 
of variation of the filled volume is determined. Several thousand vials/ampoules are usually 199 
prepared. After lyophilization, the ampoules or vials are back-filled with nitrogen and the 200 
homogeneity of the lyophilized material is determined, sampling across the batch. Testing is 201 
performed for residual moisture and oxygen which may impact product stability and 202 
accelerated (at higher temperatures) and real-time stability is determined to ascertain that the 203 
reference material can be shipped at ambient temperatures worldwide, without loss of potency 204 
under normal storage temperatures (typically -20°C) over the life of the IS. 205 
Commutability 206 
Commutability is a property of a reference material demonstrated by the closeness of 207 
agreement between the results obtained for the reference material and the results obtained for 208 
clinical specimens, when comparatively tested in different assays (36, 37). In other words, in 209 
order to be suitable as an assay calibrator, the reference material should not behave differently 210 
compared to clinical specimens. Commutability is demonstrated by testing the different 211 
materials (reference material, clinical specimens) in multiple assays. ISs are designed to 212 
reflect as closely as possible the specimens tested in routine diagnosis or blood screening. For 213 
example, human plasma or sera are very common types of sample matrices tested in blood 214 
screening and clinical laboratories and several ISs are derived from viremic donations or 215 
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contain culture-derived virus diluted in plasma. In addition, the strain of pathogen (i.e. the 216 
analyte) used for the IS is usually selected to represent the most commonly circulating variant. 217 
Commutability is an important precondition for the ability of the calibrant to harmonize 218 
different assays, and is addressed by inclusion of clinical specimens, as far as possible, in the 219 
international collaborative study. The impact of different extraction systems (reagents, 220 
equipment) on the extraction efficiencies for different matrices is another factor to be 221 
addressed in commutability studies. In the case of CMV, non-commutability of the IS has 222 
been demonstrated for some assays (38). Commutability, in the case of CMV, is particularly 223 
complex and affected by features such as the physical form of viral DNA in the IS (virion-224 
associated DNA) compared to that found in transplant patients which is highly fragmented 225 
(39, 40). Furthermore, during amplification/detection reactions, amplicon length impacts viral 226 
load determinations (40). With the development of additional IS for clinical pathogens the 227 
challenge of commutability becomes even more complex with quantitative values reported for 228 
multiple types of sample matrices, including urine, CSF and stool. In the case of CSF, it is a 229 
matrix with a low protein content which is difficult to obtain in large volumes, and is not easy 230 
to evaluate in collaborative studies or in formal commutability investigations. Stool is another 231 
challenging sample type where the matrix contains inhibitors and the sample extraction is not 232 
well standardized. 233 
International collaborative studies 234 
Candidate ISs, RRs and IPRS are evaluated in international collaborative studies. Participants 235 
volunteering to take part in these studies include blood centers, reference laboratories, clinical 236 
microbiology laboratories, manufacturers of diagnostics kits and medicinal products as well 237 
as regulatory organizations. Typically 15 to 25 laboratories will be involved in such a study. 238 
The assays included in the studies are ones used throughout the world, and include 239 
commercially available tests as well as LDTs. The studies investigate potency of the 240 
candidate materials, clinical comparator samples as well as related reference materials and 241 
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calibrators; potencies are determined using qualitative or quantitative assays as described 242 
above. One of the major aims of each study is to provide a basis for assignment of unitage to 243 
the standard; the unitage assignment is usually based on the combined mean potency for all 244 
the assays included in the study. Expressing results of the study samples against the candidate 245 
IS can greatly reduce variation in the measured potencies reported by participants, and the 246 
harmonization effect (see below) is an important factor reviewed by the ECBS to demonstrate 247 
the utility of a new IS. The studies themselves allow a head-to-head comparison of assays 248 
used throughout the world and provide information on sensitivity (based on end-point analysis 249 
of qualitative assays) as well as variability in quantification. 250 
Statistical analysis of the study data forms the basis for the final report which includes a 251 
proposal for the unitage for the IS. Participants are requested to comment on the report and 252 
asked if they agree with the proposed unitage. The final report is made available on the WHO 253 
website for public review ahead of the annual meeting of the ECBS. In the case of IRPs, no 254 
unitage is assigned to the panel members; however, details may be included in the report with 255 
the range of potencies observed. 256 
Subsequent to the establishment of a standard or panel, the custodian laboratory has a 257 
responsibility for the storage of each batch under controlled conditions, monitoring of stability 258 
and coordinating distribution worldwide. 259 
 260 
REPLACEMENT OF WHO ISs 261 
Although several thousand vials are prepared for each standard, when they are nearing 262 
exhaustion, it is essential to replace the previous preparation. Replacement projects are 263 
prioritized by the WHO. An important aspect of replacement of one standard with the next is 264 
maintaining the continuity of the IU in order to ensure that tests can be compared over time. 265 
Details of the NAT standards which have been replaced are shown in supplementary Table 266 
S1. Since it was established in 1997 (1), the HCV IS has been replaced four times (41-44). 267 
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Replacement ISs have been prepared for HBV (45-47), HAV (48, 49), HIV-1 (50-52) and 268 
B19V (53, 54). In each case, replacement preparations have been evaluated in parallel with 269 
the previous IS, using either qualitative end-point assays or quantitative assays (within the 270 
linear range) and covering appropriate dilutions. With each subsequent IS, the possibility 271 
exists for drift in the IU; this may be exacerbated by issues with assay features included in 272 
collaborative studies, such as primer/probe mismatches affecting quantification, and 273 
emphasizes the need for good characterization of starting materials. An example is the study 274 
to establish the 3
rd
 IS for B19V (54) where the new B19V viremic plasma donation used for 275 
the 3
rd
 IS was under-quantified by the COBAS TaqScreen DPX test, probably due to a 276 
mismatch between the primers/probe and the sequence of the ISs (55), impacting the assigned 277 
unitage. 278 
 279 
ASSAY HARMONIZATION USING WHO ISs 280 
Relative potencies 281 
During the establishment of WHO ISs, one of the criteria for acceptance of a new standard is 282 
the demonstration that when results of testing are expressed relative to the candidate IS, an 283 
improvement is seen in the agreement observed between assays and laboratories. 284 
An example of this is shown in Figure S1. A HEV sample, included in the collaborative study 285 
to establish the HEV IS, was evaluated using a mixture of qualitative and quantitative NAT 286 
assays – the reported potencies are shown in the upper panel showing a wide variation in titres 287 
over several orders of magnitude. By expressing these potencies against the WHO IS (PEI 288 
code number 6329/10) the agreement between laboratories is markedly improved with 289 
variation being reduced to ~ 1 log10 and a typical reduction in the associated standard 290 
deviation (SD). 291 
External Quality Assessment Programs 292 
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External quality assessment (EQA)/proficiency testing (PT) programs can be very helpful in 293 
generating data on the implementation of WHO ISs by participating laboratories in a large 294 
number of countries. In some cases, WHO ISs have been included directly in EQA studies. 295 
For example, the 1
st
 IS for ZIKV was made available by the WHO in July 2016 prior to 296 
formal establishment by the ECBS and was introduced as a consequence of the Public Health 297 
Emergency of International Concern (56). The 1
st
 ZIKV IS has been included in all the ZIKV 298 
EQA/PT programs provided by Quality Control for Molecular Diagnostics (QCMD) since 299 
2016 (57). 300 
Data analysis from QCMD EQA/PT schemes demonstrate that where an IS has been 301 
established for a specific target pathogen the observed variation (SD) based on the geometric 302 
mean of the log10 viral load results, are noticeably smaller (Table S2). This observation is 303 
based on results reported in IU/mL on duplicate panel members. In contrast, for pathogen 304 
targets where an IS has only recently been established or where there is no IS and reporting of 305 
results is often in different types of unit, the SDs are much greater (Table S2). In addition, 306 
where there is a known clinical need for pathogen quantitation then the IS and IU/mL are 307 
more readily accepted. 308 
In the case of CMV, for example, in early EQA/PT studies done prior to 2004, the majority of 309 
assays performed by laboratories participating in the CMV EQA program were qualitative 310 
(Figure S2). For quantitative assays performed prior to the establishment of the 1
st
 CMV IS in 311 
2010 (9), laboratories reported results in either copies/mL or other units of measurement such 312 
as genome equivalents/mL as observed through the data reported in international EQA/PT 313 
schemes. Over the last 8 years the number of laboratories reporting in IU/ml has increased 314 
significant from 0 to 50% of the datasets returned within the annual international EQA/PT 315 
schemes run by QCMD (Figure S3). For CMV viral load testing, the increase in reporting in 316 
IU correlates with an increase in the use of commercial assays used by participants in the 317 
QCMD studies (Figure S4). In a recently published EQA study, evaluating results reported in 318 
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IU/mL, the variation between results was lower when compared to those reported in 319 
copies/mL demonstrating the use of the CMV WHO IS improves the reproducibility and 320 
comparability of CMV viral load results across laboratories (58). Consequently, the recently 321 
revised International guidelines on the management of CMV in solid organ transplantation 322 
recommend that all results should be reported as IU/mL (59). More significant improvements 323 
in results have been reported for EBV when the IS has been used (60). 324 
 325 
PRE-QUALIFICATION OF IN VITRO DIAGNOSTIC DEVICES 326 
International reference preparations play an important role in the WHO prequalification 327 
program for IVDs. In this program, IVDs targeting low- and middle-income countries (LMIC) 328 
are independently assessed by WHO since LMIC themselves rarely have the regulatory 329 
capacity to assess the quality and suitability of IVDs offered to the national market. In WHO 330 
prequalification studies, ISs may be used for comparative evaluation of essential assay 331 
features such as sensitivity, limit of detection or range of quantitation. Furthermore, IRPs 332 
covering different variants (e.g. genotypes, recombinants) are important for the detection of 333 
strains more prevalent in certain regions. The outcome of performance evaluation studies 334 
initiated on behalf of the WHO prequalification program for IVDs is published together with 335 
a list of IVDs deemed suitable by WHO for the intended purpose. 336 
 337 
STRATEGIC ADVISORY GROUP OF EXPERTS ON IN VITRO DIAGNOSTICS 338 
(SAGE IVD) 339 
In 2017, the WHO established the Strategic Advisory Group of Experts on In Vitro 340 
Diagnostics (SAGE IVD). SAGE IVD recently published the first model list of essential 341 
diagnostics, including several NAT assays for markers including HBV, HCV, HIV, 342 
Mycobacterium tuberculosis and HPV (61). The elaboration of the list is aimed to improve 343 
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access to IVDs which are estimated essential in a given health system. The ultimate goal is 344 
strengthening of health systems and the availability of universal health coverage. This is akin 345 
to the WHO essential medicines list which includes those medicines which are deemed 346 
indispensable in a health care system. 347 
 348 
STANDARDS CURRENTLY UNDER DEVELOPMENT 349 
Standards currently under development are shown in the supplementary Table S3 and include 350 
viral and parasitic markers as well as a standard for M. tuberculosis reflecting the global 351 
burden of disease and the increasing use of molecular testing for this pathogen. 352 
 353 
CONCLUSIONS 354 
Significant progress has been made in NAT standardization over the past two decades in the 355 
context of screening for blood-borne markers as well as in clinical diagnostic laboratories. 356 
The development of WHO standards and other reference reagents (ISs, RRs and IRPs) has 357 
helped in these efforts, also enabling the introduction of regulations for the detection of blood-358 
borne pathogens in the fields of transfusion and blood product safety for markers such as 359 
HCV, HBV, HIV, HAV, B19V and more recently HEV by setting thresholds and control 360 
concentrations, defined in IUs. For clinical laboratories, for diagnosis and treatment 361 
monitoring, HCV, HBV and HIV-1 standards have been important for viral load 362 
determinations; in relation to transplantation standards established for CMV, EBV, HEV, 363 
BKV, JCV and HHV-6b are used for expression of viral loads in IU. The use of the IU 364 
improves agreement and allows comparability of data between laboratories and allows the 365 
introduction of regulations in blood screening using NAT and informs clinicians in patient 366 
testing and monitoring of therapeutic interventions. International clinical guidelines e.g. for 367 
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CMV and HEV in the transplant setting, reporting in IU is encouraged further supporting 368 
accuracy in viral load reporting and harmonization efforts (59, 62). These efforts are 369 
underpinned by the secondary standards and controls traceable in IU as well as calibrated 370 
assays. 371 
Because of their biological nature, WHO standards control for the entire NAT process – 372 
including nucleic acid extraction. Organizations such as the National Institute of Standards 373 
Technology in the US, take a different approach and produce “standard reference materials” 374 
(SRMs) for a small number of viral markers including a bacterial artificial chromosome 375 
(BAC), containing the genome of the CMV Towne strain and a linearized plasmid DNA 376 
control for BK virus. These SRMs are added directly to the amplification/detection reaction 377 
without undergoing prior extraction and are intended to be used for the calibration of controls 378 
and standards. Some organizations provide in vitro transcribed RNAs (IVTs), and like the 379 
NIST materials these materials do no control for the extraction part of the NAT assay. In a 380 
study organized by kit manufacturers, a partial HCV IVT RNA was evaluated in a study 381 
comparing amplification methods; however it was not found to perform better than the 382 
biological standard (63). During the study to establish the 1
st
 WHO IS for CMV, the candidate 383 
standard, based on a clinical strain (Merlin) propagated in cell culture, was evaluated in 384 
parallel with BAC containing the entire Merlin genome. Participants added the BAC directly 385 
to the amplification reactions. Expression of potencies of other cultured virus preparations 386 
against the candidate IS showed marked reduction in variation between laboratories, however, 387 
when the results were expressed relative to the BAC no improvement was observed compared 388 
to the absolute mean estimates (9). In the study to establish the 1
st
 WHO IS for ZIKV, 389 
expression of clinical samples and biological reference materials saw an improvement in 390 
agreement of results between laboratories. In the study, two related IVTs were included – one 391 
containing several assay target sequences in a single transcript and the second preparation a 392 
mixture of the respective individual IVT RNAs. Expressions of the one IVT preparation 393 
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against the other resulted in harmonization, however, expression of clinical samples or 394 
biological reference materials against the IVTs failed to produce any improvement (17). 395 
These studies demonstrate the importance of controlling the extraction step in the NAT 396 
procedure and emphasizes the advantage of the approach taken by the WHO compared with 397 
(bio)-synthetic types of reference material. However, the latter may be easier to replace 398 
compared to sourcing, for example, new viremic donations in the case of some of the WHO 399 
ISs. 400 
Sequence data is available for most WHO ISs, RRs and IRPs (Table 1, supplementary 401 
information and Tables S4-S7), sometimes indicating sequence heterogeneities when 402 
compared to clinical isolates, e.g. sequence deletions or sequence duplications in culture 403 
based materials. Using next generation sequencing data, even subpopulations of sequence 404 
variants are being detected, as was reported recently for the ISs BK and JC polyoma viruses 405 
(64, 65). Passage of the strains in cell culture resulted in heterogeneous DNA populations, the 406 
reason for which is not understood and which could affect some specialized assays (64, 65), 407 
although both preparations were shown to successfully harmonize assay performance in the 408 
collaborative studies (11, 12) and in independent studies (66). These observations demonstrate 409 
the importance in thorough characterization of the starting materials used for standard 410 
preparation. Methods such as digital PCR are useful in the characterization process in 411 
understanding the relationship between IU and copy number ratios for specific methods as 412 
well as for estimating potency during development of new ISs or when no standard exists. In 413 
the case of the 1
st
 WHO IS for HAV, the IU:copy number ratio was determined to be 1:14 414 
using digital PCR (S. Baylis unpublished data) and the low IU value was a consequence of 415 
low sensitivity of assays used by participants in the original collaborative study (5). 416 
With the absence of reference methods to define nucleic acid content of microbial pathogens 417 
in complex biological matrices, this emphasizes the validity of WHO approach in the 418 
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development of reference standards and harmonizing NAT assays. However, the challenge for 419 
the development of such standard remains meeting the clinical need in a timely manner whilst 420 
maintaining rigorous procedures in the establishment process. Adequate commutability of ISs 421 
is essential particularly in the clinical setting and will affect treatment of patients and hinder 422 
the introduction of clinical practice guidelines. Inclusion of sufficient clinical materials in 423 
studies to evaluate commutability remains a problem in terms of volume, transfer agreements 424 
and the support of the wider scientific community in these efforts is essential to fully realize 425 
the potential of the WHO standardization efforts. 426 
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FIGURE LEGENDS 435 
Figure 1 Hierarchy of standards 436 
The relationship between ISs and secondary and tertiary standards is shown together with 437 
their uses. 438 
Figure 2 Process for the development of WHO ISs, RRs and IRPs 439 
The procedure is shown from the identification of a scientific need to develop a standard to its 440 
establishment and ultimately its replacement. cIS – candidate International Standard. 441 
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Table 1 Current viral and microbial WHO International Standards and Reference Reagents for NAT 
International Standards and Reference Reagents for NAT 
Preparation (unitage) Standard (code number) Material (accession no.)* Year of 
establishment 
Reference 
BK virus DNA 
(10,000,000 IU/vial) 
1st International Standard 
(14/212) 
Cultured BK virus, diluted in buffer/human serum 
albumin/trehalose 
2015 11 
Chikungunya virus RNA 
(1,250,000 IU/vial) 
1st International Standard 
(11785/16) 
Cultured and heat inactivated R91064 strain diluted in 
human plasma (KJ941050). 
2017 18 
Dengue virus RNA 
(13,500 units/vial) 
1st Reference Reagent Cultured and heat inactivated Hawaii strain diluted in 
human plasma (KM204119). 
2016 20 
Dengue virus RNA 
(69,200 units/vial) 
1st Reference Reagent Cultured and heat inactivated New Guinea C strain 
diluted in human plasma (KM204118). 
2016 20 
Dengue virus RNA 
(23,400 units/vial) 
1st Reference Reagent Cultured and heat inactivated H87 strain diluted in 
human plasma (KU050695). 
2016 20 
Dengue virus RNA 
(33,900 units/vial) 
1st Reference Reagent Cultured and heat inactivated H241 strain diluted in 





1st Reference Reagent 
(15/222) 
Lentiviral vector encoding Ebola genes np-vp35-gp in 
buffer/human serum albumin/trehalose (KT186367). 
2015 19 
Ebola virus VP40-L 
(50,000,000 units/vial) 
1st Reference Reagent 
(15/224) 
Lentiviral vector encoding Ebola vp40-L genes in 
buffer/human serum albumin/trehalose (KT186368). 
2015 19 
Epstein Barr virus DNA 
(5,000,000 IU/vial) 
1st International Standard 
(09/260) 
Cultured EBV B95-8 strain, diluted in buffer/human 










International Standards and Reference Reagents for NAT 
Preparation (unitage) Standard (code number) Material (accession no.)* Year of 
establishment 
Reference 
Hepatitis A virus RNA 
(15,451 IU/vial) 
3rd International Standard 
(15/276) 
Viremic human plasma (KY003229). 2017 49 
Human cytomegalovirus 
DNA (5,000,000 IU/vial) 
1st International Standard 
(09/162) 
Cultured Merlin strain, diluted in buffer/human serum 
albumin/trehalose (AY446894). 
2010 9 
Hepatitis B virus DNA 
(477,500 IU/vial) 
4th International Standard 
(10/266) 
Viremic human plasma representing HBV genotype 
A2, HBsAg subtype adw2 (KY003230). 
2016 47 
Hepatitis C virus RNA 
(100,000 IU/vial) 
5th International Standard 
(14/150) 
Viremic human plasma representing HCV genotype 1 2015 44 
Hepatitis D virus RNA 
(287,500 IU/ml) 
1st International Standard 
(7657/12) 
Viremic human plasma (HQ005369). 2013 8 
Hepatitis E virus RNA 
(125,000 IU/vial) 
1st International Standard 
(10/6329) 
Viremic human plasma representing HEV genotype 3a 
(AB630970). 
2011 7 
HIV-1 RNA (125,893 
IU/vial) 
4th International Standard 
(16/194) 
Cultured and heat inactivated subtype B isolate diluted 
in human plasma (KJ019215). 
2017 52 
HIV-2 RNA (1,000 
IU/vial) 
1st International Standard 
(08/150) 
Cultured and heat inactivated CAM2 strain diluted in 
human plasma (KU179861). 
2009 6 
Human Herpes Virus 6B 
(56,234,132 IU/vial) 
1st International Standard 
(15/266) 
Cultured HHV-6B strain Z-29, diluted in buffer/human 
serum albumin/trehalose (AF157706). 
2017 13 
Human papilloma virus 
type 16 DNA (5,000,000 
1st International Standard 
(06/202) 











International Standards and Reference Reagents for NAT 




Human papilloma virus 
type 18 DNA (5,000,000 
IU/vial) 
1st International Standard 
(06/206) 
HPV type 18 plasmid DNA diluted in buffer/trehalose 
(X05015). 
2008 21 
JC virus DNA 
(10,000,000 IU/vial) 
1st International Standard 
(14/114) 





1st International Standard 
(8293/13) 
Cultured Mycoplasma fermentans, in Mycosafe Friis 
medium 
2013 16 
Parvovirus B19 DNA 
(705,000 IU/vial) 
3rd International Standard 
(12/208) 




1st International Standard 
(04/176) 
Parasitemic human blood 2006 14 
Toxoplasma gondii 
(500,000 IU/vial) 
1st International Standard 
(10/242) 
T. gondii tachyzoites obtained from infected mice, 
diluted in buffer/trehalose 
2014 15 
Zika virus RNA 
(25,000,000 IU/vial) 
1st International Standard 
(11468/16) 
Cultured and heat inactivated PF13/251013-18 strain 
diluted in stabilizer (KX369547). 
2016 17 










Table 2 Current International Reference Panels for NAT (viral markers) 
International Reference Panels for NAT 
Panels (No. of 
members) 
Standard (code number) Material Year of 
establishment 
Reference 
Hepatitis B Virus 
genotypes (15) 
1st International Reference 
Panel (5086/08) 
Viremic plasma diluted in pooled human plasma; HBV 
genotypes A-G 
2009 33 
Hepatitis E virus 
genotypes (11) 
1st International Reference 
Panel (8578/13) 
Viremic plasma donations and stool samples diluted in 
pooled human plasma; HEV genotypes 1a, 1e, 2a, 3b, 
3c, 3e, 3f/l, 3 ra, 4c, 4g 
2015 34 
HIV-1 subtypes (10) 1st International Reference 
Panel (01/466) 
Cultured HIV-1 subtypes A, B, C, D, AE, F, G, AG-
GH, N and O diluted in human plasma 
2003; replaced 
in 2012 by 
12/224 
30 
HIV-1 subtypes (10) 2nd International Reference 
Panel (12/224) 
Cultured and heat inactivated HIV-1 subtypes A, B, C, 




recombinant forms (10) 
1st International Reference 
Panel (13/214) 
Cultured and heat inactivated HIV-1 CRFs and 




1st International Reference 
Panel (09/110; CBER 
Parvovirus B19 Genotype 
Panel 1) 
Viremic plasma donations diluted in pooled human 
plasma; B19V genotypes 1a1, 2, 3a and negative 
plasma control 
2009 34 
*Sequence details for IRP members are available in supplementary information (text and Tables S4-S7). 
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